Salt forms of bempedoic acid and methods for using the same

-4. (canceled)

The crystalline form of claim 61, wherein the crystalline form is the crystalline calcium salt of the compound of formula (V):

• wherein the crystalline calcium salt of the compound of formula (V) is characterized by an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ):
• 4.9±0.2°, 9.1±0.2°, and 19.7±0.2°.

-7. (canceled)

The crystalline form of claim 61, wherein the crystalline form is the crystalline calcium salt of the compound of formula (V):

• wherein the crystalline calcium salt of the compound of formula (V) is characterized by an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ):
• 6.0±0.2°, 6.8±0.2°, 8.5±0.2°, and 9.8±0.2°.

-10. (canceled)

The crystalline form of claim 61, wherein the crystalline form is the crystalline diethylamine salt of the compound of formula (V):

• wherein the crystalline diethylamine salt of the compound of formula (V) is characterized by an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ):
• 9.6±0.2°, 14.1±0.2°, and 19.8±0.2°.

(canceled)

The crystalline form of claim 61, wherein the crystalline form is the crystalline ethylenediamine salt of the compound of formula (V):

• wherein the crystalline ethylenediamine salt of the compound of formula (V) is characterized by an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ):
• 10.8±0.2°, 16.2±0.2°, and 18.3±0.2°.

-16. (canceled)

The crystalline form of claim 61, wherein the crystalline form is the crystalline isonicotinamide salt of the compound of formula (V):

• wherein the crystalline isonicotinamide salt of the compound of formula (V) is characterized by an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ):
• 4.4±0.2°, 18.8±0.2°, 20.1±0.2°, and 24.5±0.2°.

-19. (canceled)

The crystalline form of claim 61, wherein the crystalline form is the crystalline potassium salt of the compound of formula (V):

• wherein the crystalline potassium salt of the compound of formula (V) is characterized by an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ):
• 5.7±0.2°, 7.3±0.2°, 9.6±0.2°, and 22.1±0.2°.

-22. (canceled)

The crystalline form of claim 61, wherein the crystalline form is the crystalline L-lysine salt of the compound of formula (V):

• wherein the crystalline L-lysine salt of the compound of formula (V) is characterized by an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ):
• 4.2±0.2°, 19.1±0.2°, and 21.9±0.2°.

-26. (canceled)

The crystalline form of claim 61, wherein the crystalline form is the crystalline sodium salt of the compound of formula (V):

• wherein the crystalline sodium salt of the compound of formula (V) is characterized by an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ):
• 6.1±0.2°, 14.2±0.2°, 18.3±0.2°, and 24.5±0.2°.

-29. (canceled)

The crystalline form of claim 61, wherein the crystalline form is the crystalline ammonium salt of the compound of formula (V):

• wherein the crystalline ammonium salt of the compound of formula (V) is characterized by an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ):
• 7.1±0.2°, 14.3±0.2°, and 16.0±0.2°.

-33. (canceled)

The crystalline form of claim 61, wherein the crystalline form is the crystalline piperazine salt of the compound of formula (V):

• wherein the crystalline piperazine salt of the compound of formula (V) is characterized by an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ):
• 6.7±0.2°, 15.7±0.2°, and 16.0±0.2°.

-37. (canceled)

The crystalline form of claim 61, wherein the crystalline form is the crystalline tromethamine salt of the compound of formula (V):

• wherein the crystalline tromethamine salt of the compound of formula (V) is characterized by an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ):
• 6.6±0.2°, 18.2±0.2°, 18.6±0.2°, and 19.8±0.2°.

-40. (canceled)

The co-crystal of claim 62, wherein the co-crystal is the cocrystal of aspartame and the compound of formula (V):

-43. (canceled)

The co-crystal of claim 62, wherein the co-crystal is the cocrystal of aspartame and the compound of formula (V):

• wherein the cocrystal of aspartame and the compound of formula (V) is characterized by an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ):
• 7.6±0.2°, 17.3±0.2°, and 18.4±0.2°.

-47. (canceled)

The co-crystal of claim 62, wherein the co-crystal is the cocrystal of aspartame and the compound of formula (V):

• wherein the cocrystal of aspartame and the compound of formula (V) is characterized by an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ):
• 4.4±0.2°, 10.6±0.2°, and 18.4±0.2°.

-51. (canceled)

The co-crystal of claim 62, wherein the co-crystal is the cocrystal of palmitic acid and the compound of formula (V):

(canceled)

The co-crystal of claim 62, wherein the co-crystal is the cocrystal of palmitic acid and the compound of formula (V):

• wherein the cocrystal of palmitic acid and the compound of formula (V) is characterized by an X-ray powder diffraction pattern comprising peaks at the following diffraction angles (2θ):
• 4.3±0.2°, 6.3±0.2°, 8.5±0.2°, and 17.0±0.2°.

-57. (canceled)

A method of lowering LDL-C or treating cardiovascular disease, the method comprising administering to a patient a therapeutically-effective amount of the crystalline form of the compound of formula (V) of claim 61.

-60. (canceled)

A crystalline form of the compound of formula (V):

• wherein the crystalline form is selected from the group consisting of a crystalline betaine salt, a crystalline calcium salt, a crystalline diethylamine salt, a crystalline ethylenediamine salt, a crystalline isonicotinamide salt, a crystalline potassium salt, a crystalline L-lysine salt, a crystalline sodium salt, a crystalline ammonium salt, a crystalline piperazine salt, and a crystalline tromethamine salt.

A co-crystal comprising the compound of formula (V):

• wherein the co-crystal is a cocrystal of aspartame and the compound of formula (V), or a cocrystal of palmitic acid and the compound of formula (V).